Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DR26FMDU5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $25,532
Award facts
- Contract value 100% obligated
- $25,532.04 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $25,532.04 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg tablets (120-count units). The delivery order, issued on October 28, 2025, with an ultimate completion date of October 29, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.999 billion ceiling value and completion date of December 31, 2036.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier supporting the Department of Defense's medical supply chain requirements. The PPV-G GEN V program represents a $30.3 billion acquisition strategy designed to provide multiple regional prime vendor contractors to deliver a comprehensive range of pharmaceuticals—including branded and generic prescription drugs, biologics, vaccines, and medical consumables—to military healthcare facilities worldwide. This specific delivery order for Xtandi, an oncology treatment, exemplifies the vendor's capability to fulfill specialized pharmaceutical requirements essential to Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DR26FMDU5?
SPE2DR26FMDU5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 28, 2025.
How much is contract SPE2DR26FMDU5 worth?
The government has obligated $25,532 on SPE2DR26FMDU5.
Is contract SPE2DR26FMDU5 an order under another contract?
Yes. SPE2DR26FMDU5 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDU5 competed?
The extent of competition for SPE2DR26FMDU5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award